Combo bests standard care in younger CLL patients

Print Friendly, PDF & Email


2018 ASH Annual Meeting
©ASH/Scott Morgan 2018
In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger than 70 with untreated chronic lymphocytic leukemia (CLL). Patients who received IR had superior progression-free survival (PFS) and overall survival compared to patients who received fludarabine, cyclophosphamide, and rituximab... [Read Article]
Print Friendly, PDF & Email

Lymphodepletion improves efficacy of CAR T cells in HL

Print Friendly, PDF & Email


Crowd exiting a session at the 2018 ASH Annual Meeting
© ASH/Rodney White 2018
A phase 1 study suggests lymphodepletion can improve the efficacy of CD30-directed chimeric antigen receptor (CAR) T-cell therapy in patients with Hodgkin lymphoma (HL). Researchers observed improved responses in HL patients treated with fludarabine and cyclophosphamide prior to CD30.CAR... [Read Article]
Print Friendly, PDF & Email

Fludarabine deemed important for CD30.CAR T-cell therapy

Print Friendly, PDF & Email


Attendees at ASH 2018
Photo courtesy of ASH
Fludarabine is “very important” for lymphodepletion prior to CD30-directed chimeric antigen receptor (CAR) T-cell therapy, according to a presentation at the 2018 ASH Annual Meeting. A phase 1/2 study showed that bendamustine alone was not sufficient as lymphodepletion. However, adding fludarabine to bendamustine could enhance responses... [Read Article]
Print Friendly, PDF & Email

Shorter R-CHOP regimen noninferior in certain DLBCL patients

Print Friendly, PDF & Email


Viola Poeschel, MD
© ASH/Scott Morgan 2018
A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy was noninferior in efficacy to the standard six cycles of R-CHOP in younger patients with favorable-risk diffuse large B-cell lymphoma (DLBCL), according to investigators of the FLYER trial. In addition,... [Read Article]
Print Friendly, PDF & Email

Regimen provides survival benefit in PTCL

Print Friendly, PDF & Email


Attendees at ASH 2018
Photo courtesy of ASH
A newly approved treatment regimen provides a survival benefit over standard therapy for patients with CD30-positive peripheral T-cell lymphomas (PTCLs), according to a presentation at the 2018 ASH Annual Meeting. In the ECHELON-2 trial, patients who received brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone (CHP) had... [Read Article]
Print Friendly, PDF & Email

New PCNSL guidelines emphasize importance of patient fitness

Print Friendly, PDF & Email


Micrograph showing PCNSL
Image by Michael Bonert
New guidelines on the diagnosis and management of patients with primary central nervous system lymphoma (PCNSL) emphasize prompt diagnosis, aggressive treatment whenever possible, and multidisciplinary team support. A unique aspect for hematologic cancers, the guideline authors wrote, is that appropriate treatment requires input from neurology specialists. And they... [Read Article]
Print Friendly, PDF & Email

EC approves mogamulizumab for MF, SS

Print Friendly, PDF & Email


Micrograph showing
mycosis fungoides
The European Commission (EC) has granted marketing authorization for mogamulizumab (Poteligeo), a humanized monoclonal antibody directed against CCR4. This means mogamulizumab is approved for use in adults with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. This approval is valid in all... [Read Article]
Print Friendly, PDF & Email

Pegfilgrastim biosimilar approved by EC

Print Friendly, PDF & Email


Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer
The European Commission (EC) has granted marketing authorization for Sandoz’s pegfilgrastim product Ziextenzo®, a biosimilar of Amgen’s Neulasta. Ziextenzo is approved for the same use as the reference medicine—to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults receiving cytotoxic chemotherapy for... [Read Article]
Print Friendly, PDF & Email

EC approves pegfilgrastim biosimilar

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
The European Commission (EC) has approved Mundipharma’s pegfilgrastim product Pelmeg, a biosimilar of Amgen’s Neulasta. Pelmeg is approved for use in reducing the duration of neutropenia and the incidence of febrile neutropenia in adults who receive cytotoxic chemotherapy for malignancies, with the exceptions of chronic... [Read Article]
Print Friendly, PDF & Email